These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1763518

  • 1. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
    Muralidharan G, Hawes EM, McKay G, Midha KK.
    Xenobiotica; 1991 Nov; 21(11):1441-50. PubMed ID: 1763518
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G, Midha KK, McKay G, Hawes EM, Inaba T.
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [Abstract] [Full Text] [Related]

  • 4. Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation.
    Coutts RT, Bolaji OO, Su P, Baker GB.
    Drug Metab Dispos; 1994 Feb; 22(5):756-60. PubMed ID: 7835228
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    Tyndale RF, Kalow W, Inaba T.
    Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
    [Abstract] [Full Text] [Related]

  • 16. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
    Barham HM, Lennard MS, Tucker GT.
    Biochem Pharmacol; 1994 Apr 20; 47(8):1295-307. PubMed ID: 8185638
    [Abstract] [Full Text] [Related]

  • 17. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.
    Roy SD, Hawes EM, McKay G, Hubbard JW, Midha KK.
    Can J Physiol Pharmacol; 1985 Jul 20; 63(7):778-81. PubMed ID: 3876145
    [Abstract] [Full Text] [Related]

  • 18. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
    Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB.
    Mol Pharmacol; 1991 Jul 20; 40(1):63-8. PubMed ID: 1857341
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW, Hayhurst GP, Lightfoot T, Smith G, Harlow J, Rowland-Yeo K, Larsson C, Mahling J, Lim CK, Wolf CR, Blackburn MG, Lennard MS, Tucker GT.
    Biochem J; 2000 Feb 01; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.